ARTICLE | Clinical News

Plinabulin: Phase II data

September 28, 2015 7:00 AM UTC

An open-label, international Phase II trial in 105 patients with advanced NSCLC showed that 30 mg/m 2 plinabulin plus docetaxel missed the primary endpoint of improving median OS vs. docetaxel alone (8.7 vs. 7.5 months, p=0.87). Plinabulin plus docetaxel also missed the secondary endpoint of improving median PFS vs. docetaxel (2.8 vs. 3.5 months, p=0.41). Plinabulin plus docetaxel led to a 6-month OS rate of 64% vs. 65.5% for docetaxel (p=0.88), an overall response rate (ORR) of 14% vs. 14.5% for docetaxel (p=0.94) and a median duration of response of 12.7 months vs. 1.5 months for docetaxel (p=0.049). ...